A drug approval can be real while leaving important questions open. Forzinity offers a striking example: FDA approved it after a study that did not show superiority to placebo on its primary endpoints, while longer-term observations supported a narrower muscle-strength indication.[1] Reading those findings together helps explain the scope of the approval and why its conclusions cannot simply be assigned to any research vial bearing the same compound name.
The approval that followed a failed primary endpoint
On September 19, 2025, FDA approved Forzinity (elamipretide), from Stealth Biotherapeutics, as an injection given under the skin to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg.[1]
Barth syndrome is a rare, genetically confirmed disease, and the drug is described as a mitochondrial cardiolipin binder — a description of its interaction with cardiolipin in mitochondria.[1]
Readers who follow research materials may know elamipretide by its laboratory name, SS-31. That dual identity is why this approval deserves a careful read: the same molecule can exist as an approved medicine, a clinical-trial preparation, and a research reagent, and those are three different things.
Inside the trial: twelve patients and a long extension
The approval rested on one study, SPIBA-201, which enrolled 12 patients with genetically confirmed Barth syndrome at a single site in the United States.[1]
The first part used a randomized, double-blind, placebo-controlled crossover design, with the key efficacy comparison after 12-week treatment periods.[1]
The primary endpoints were the distance walked in a 6-minute walk test and the Total Fatigue Score on the Barth Syndrome Symptom Assessment, and Forzinity was not superior to placebo on either of them.[1]
That is the honest negative finding, stated plainly: on the measures the trial was built around, the drug did not beat placebo during the controlled period.
What changed the picture was a secondary endpoint. Knee extensor muscle strength, measured by handheld dynamometry, showed no statistically significant difference during the randomized period — a median change of minus 5 newtons on placebo versus plus 4 newtons on drug at week 12 — but larger increases appeared during a 192-week open-label extension that 10 of the 12 patients entered, with 8 participating through week 168.[1]
| Trial period | Visit | Patients (N) | Median change in knee extensor strength (newtons) |
|---|---|---|---|
| Randomized controlled trial | Week 12, placebo | 12 | -5 |
| Randomized controlled trial | Week 12, Forzinity | 12 | +4 |
| Open-label extension | Week 12 | 10 | +34 |
| Open-label extension | Week 24 | 9 | +68 |
| Open-label extension | Week 36 | 8 | +57 |
| Open-label extension | Week 48 | 8 | +41 |
| Open-label extension | Week 72 | 8 | +35 |
| Open-label extension | Week 168 | 8 | +63 |
Baseline median strength at the start of the randomized trial was 124 newtons.[1] The table shows larger numerical changes during the extension, while the shrinking number of participants and absence of a concurrent placebo arm limit the comparison.
What accelerated approval actually means
FDA states that Forzinity was approved under its accelerated approval program, which provides earlier patient access to a promising new drug while the company continues to conduct clinical trials to confirm that the drug works well.[1]
Two qualifications follow from that, and both come straight from the record. First, the indication granted was narrow — to improve muscle strength — not to improve walking distance or fatigue, the endpoints that missed. Second, the strength evidence itself came from an open-label extension, meaning there was no placebo comparison during the period when the gains appeared; the snapshot itself notes that a significant difference was not shown during the initial 12-week randomized portion and that the observed increases occurred during the longer, open-label period.[1]
Open-label data are real data, and for a rare disease they can be decisive. They are also easier for expectation effects, natural history, and attrition to color — which is why confirmation trials are part of the bargain.
Who the evidence actually describes
All 12 trial participants were male, aged 12 years or older, and not Hispanic or Latino, and all but one were White, with one American Indian or Alaska Native patient.[1]
Because every participant was male, nearly all were of one racial background, and the number completing the extension was small, subgroup analyses for efficacy were not conducted.[1]
Supportive safety information came from other clinical trials of Forzinity in different disease populations, but the efficacy story is twelve males with Barth syndrome at one center.[1]
The population is a boundary of the evidence. These findings cannot, by themselves, establish a benefit for healthy adults seeking greater energy or longer life.
The side-effect record is part of the approval
Some people taking Forzinity have had allergic reactions, and in some cases these were serious and required emergency medical care, with effects ranging from rash and itchy, inflamed skin to breathing problems including coughing.[1]
Injection-site reactions were essentially universal in the randomized trial: every Forzinity-treated patient, 12 out of 12, had a local administration reaction, compared with 8 of 12 on placebo, and all 12 treated patients had injection-site redness versus 3 of 12 on placebo.[1]
These are disclosed, managed risks in an approved medicine with a prescribing information sheet and medical oversight. They are also a reminder that injecting this molecule is not a benign act even in its approved, quality-controlled form.
An approval attaches to a product and a use, not a molecule everywhere
So what does the Forzinity approval cover? A defined product, made to drug quality standards, for a defined use — improving muscle strength in Barth syndrome patients of at least 30 kg — under a program that requires further confirmation.[1]
It would be wrong to call elamipretide simply "an unapproved research chemical," because for that defined use it is approved. It would be equally wrong to let the approval wash over every vial of SS-31 sold for laboratory research. A research reagent is not the approved medicine, and a label or purity figure on a research vial cannot establish medicinal equivalence, sterility, microbiological quality, exposure, or suitability for human use.
A June 2026 FDA warning letter to an online peptide vendor concerned entirely different compounds — products marketed as Prostamax and Gonadorelin — and made no finding about elamipretide, but its general observations frame the distinction: injectable drug products can pose risks of serious harm because they bypass some of the body's key defenses against toxins and microorganisms, and "research use only" wording on a label does not by itself settle what a product is really for.[2]
Research materials should not be consumed or self-administered. The approved medicine has a defined indication, a studied preparation and a documented safety record that includes clinically important warnings. A matching compound name or purity figure cannot establish that a research vial has the same formulation, quality controls or clinical performance. The approval remains meaningful within its scope; it is not a general endorsement of every proposed use of SS-31.